美迪西(688202.SH)澄清:未參與吉利德瑞德西韋等抗肺炎藥物研發
格隆匯2月5日丨美迪西(688202.SH)午間發佈澄清公告稱,2020年1月31日,公司與呼吸疾病國家重點實驗室、廣州恩寶生物醫藥科技有限公司之間達成科研攻關合作協議。美迪西不享有合作研究成果後續帶來的經濟效益,該合作對公司的業務和經營沒有任何影響,該研發結果存在不確定性。
吉利德科學公司不是公司的重要客户。公司沒有參與吉利德科學公司Remdesivir(瑞德西韋)等抗肺炎藥物的研發,吉利德科學公司對Remdesivir(瑞德西韋)抗肺炎藥物的研發結果不會對公司的業務和收入產生任何影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.